Genmab maintains 2026 revenue guidance at USD 4.33 billion to USD 4.53 billion

Bitget2026/11/05 16:18

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Genmab maintained 2026 revenue guidance of USD 4.33 billion–USD 4.53 billion, implying 19% growth at the midpoint.
Adjusted operating profit is forecast at USD 1.07 billion–USD 1.39 billion, with adjusted operating expenses of USD 2.81 billion–USD 2.95 billion.
Spending targets accelerated late-stage development of petosemtamab and Rina-S, alongside launch preparations.
EPKINLY sales and continued royalty portfolio momentum support the revenue outlook.
Nine-month revenue rose 22% to USD 3.24 billion; adjusted operating profit increased 9% to USD 1.11 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Genmab maintains 2026 revenue guidance at USD 4.33 billion to USD 4.53 billion

You may also like

Crypto prices